Skip to content
TheChatArchiveThe Chat Archive
gpt-4o-2024-08-06· OpenAIAi2 WildChat-4.8M (AI2)

You act as a paraphrase tool. Your role involves understanding the provided text…

  1. User

    System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :

    User: We do not own any manufacturing facilities. We utilize contract manufacturing organizations, or CMOs, to formulate and produce our drug candidates and to produce our SCS Microinjector. We procure active pharmaceutical ingredients for our drugs from third-party suppliers. We expect to continue to utilize third-party manufacturers to produce quantities of our drug candidates and the SCS Microinjector. On May 8, 2018, we entered into a supply agreement with Gerresheimer Regensburg GmbH to supply our SCS Microinjector. Unless terminated earlier pursuant to its terms, the Gerresheimer agreement has an initial term of five years, after which it renews in three-year increments unless either party gives notice of non-renewal at least one year in advance. Each party has the right to terminate the agreement for customary reasons such as material breach and bankruptcy. The Gerresheimer agreement contains provisions relating to compliance by Gerresheimer with current Good Manufacturing Practices, regulations promulgated by the FDA, confidentiality and other customary matters for an agreement of this nature. We may enter into commercial supply agreements with our other suppliers. Assistant:

  2. Assistant

    Positive: We do not possess any manufacturing facilities. We rely on contract manufacturing organizations (CMOs) to develop and produce our drug candidates as well as our SCS Microinjector. We source active pharmaceutical ingredients for our drugs from external suppliers. We expect to keep using third-party manufacturers for the production of our drug candidates and the SCS Microinjector. On May 8, 2018, we signed a supply agreement with Gerresheimer Regensburg GmbH to provide our SCS Microinjector. If not terminated earlier according to its terms, the Gerresheimer agreement initially lasts five years, renewing every three years unless a party gives a non-renewal notice at least a year prior. Either party can terminate the agreement for standard reasons such as a significant breach or bankruptcy. The Gerresheimer agreement includes clauses about Gerresheimer's compliance with current Good Manufacturing Practices, FDA regulations, confidentiality, and other usual matters for an agreement like this. We might enter commercial supply agreements with other suppliers.

    Negative: We own manufacturing facilities and do not make use of contract manufacturing organizations (CMOs) to formulate and produce our drug candidates or our SCS Microinjector. We produce our own active pharmaceutical ingredients, thus not needing third-party suppliers. We do not plan to engage third-party manufacturers for manufacturing our drug candidates or the SCS Microinjector. On May 8, 2018, we did not enter into any agreement with Gerresheimer Regensburg GmbH regarding our SCS Microinjector. There is no term for renewal, termination considerations, or clauses concerning Good Manufacturing Practices or FDA regulations in any such agreement. We do not anticipate entering into commercial supply agreements with any other suppliers.